Ahmed E. Ghazi, MD

Dr. David Cohen is an assistant professor of orthopaedic surgery at the Johns Hopkins School of Medicine. His areas of clinical expertise include spine and back disorders, spinal injuries and cervical degenerative disc disease and injury.Dr. Cohen earned his M.D. from the University of Rochester School of Medicine and Dentistry and his M.P.H. from the Johns Hopkins School of Public Health. He completed his residency at The Johns Hopkins Hospital and performed a fellowship in Spinal Reconstructive Surgery at Johns Hopkins.Dr. Cohen’s research interests include scoliosis, spinal deformities, patient safety, clinical outcomes studies, vertebral augmentation and the development of a large animal osteoporosis model.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer.Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research.Specific research projects include:1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103).2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs;3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs.

Dr. Nirmish Singla is an Associate Professor of Urology and Oncology in the Brady Urological Institute at Johns Hopkins University, where he serves as the Director of Translational Research in Genitourinary Oncology. He is also the Director of the Kidney Cancer Program and co-directs the Upper Tract Urothelial Cancer (UTUC) Program as a founding member of the first-ever UTUC Multidisciplinary Clinic. He represents the Sidney Kimmel Comprehensive Cancer Center (SKCCC) on the National Comprehensive Cancer Network (NCCN) Testicular Cancer Guidelines Panel and helps lead the Testicular Cancer Program. He serves the Brady in a leadership capacity as Vice Chair and Physician Advisor for Quality, Safety, & Service; Faculty Senator for the Department of Urology; and as a core faculty member for the Hopkins Business of Health Initiative (HBHI).Dr. Singla received his undergraduate degree (B.S.E.) in Biomedical Engineering from the University of Michigan and his medical degree (M.D.) from the University of Michigan Medical School, where he was supported by a full-tuition Dean’s Merit Scholarship. He went on to complete his residency training in Urologic Surgery at the University of Texas Southwestern Medical Center (UTSW). Following his residency, he received an NIH/NCI Ruth L. Kirschstein National Research Service Award T32 grant and spent an additional year at UTSW as a postdoctoral research fellow in Urologic Oncology with a specialized translational focus in kidney cancer through the Physician Scientist Training Program. During this time, he earned a Master of Science in Clinical Science (M.S.C.S.) degree through the Center for Translational Medicine at UTSW and helped develop and pioneer a Physician Administrative Fellowship program. He then completed an advanced surgical fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York through the Society of Urologic Oncology (SUO) before joining the faculty at Johns Hopkins.Dr. Singla’s clinical practice spans the complete spectrum of genitourinary oncology, including adrenal, kidney, upper tract, bladder, prostate, penile, urethral, and testicular cancers. His surgical approaches include mastery of both open and minimally-invasive (endoscopic, laparoscopic, and robotic) techniques. Dr. Singla provides personalized and compassionate care for patients affected by urologic cancer by integrating cutting-edge technologies and multidisciplinary approaches to treatment.As both a surgeon-scientist and clinical trialist, Dr. Singla’s overarching goal is to help scientific discoveries in the laboratory materialize for patients with urologic cancers in the clinic. He runs a well-funded, multidisciplinary, translational laboratory specializing in kidney cancer, testicular cancer, and UTUC. Dr. Singla has co-authored over 200 articles and textbook chapters, and he has developed an international reputation as a thought leader in urologic oncology. He has secured a substantial amount of research funding and serves as the lead PI on multiple grants from federal, foundational, intramural, and private sources across various GU malignancies.